Drugs with Dosage: TABLET
✉ Email this page to a colleague
Drugs with Dosage: TABLET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | Dosage |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol | SOTYKTU | deucravacitinib | TABLET;ORAL | 214958-001 | Sep 9, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | TABLET;ORAL | ||||
Bristol | SOTYKTU | deucravacitinib | TABLET;ORAL | 214958-001 | Sep 9, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | TABLET;ORAL | ||
Bristol | SOTYKTU | deucravacitinib | TABLET;ORAL | 214958-001 | Sep 9, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | TABLET;ORAL | ||||
Bristol | SOTYKTU | deucravacitinib | TABLET;ORAL | 214958-001 | Sep 9, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | TABLET;ORAL | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration | >Dosage |